hyperlipidemic

Probucol is an anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.

Tenivastatin (Simvastatin acid) is an anti-hyperlipidemic HMG-CoA reductase inhibitor that inhibits the production of reactive oxygen species (ROS) and can be used in the study of primary hyperlipidemia.

1. Gelsemine (Gelsemin) has antitumor activity. 2. Gelsemine has anti-oxidative activity. 3. Gelsemine has anti-hyperlipidemic activity. 4. Gelsemine has marked antinociception in inflammatory, neuropathic and bone cancer pains without inducing antinociceptive tolerance.

'(2R)-Flavanomarein, a major flavonoid from Coreopsis tinctoria Nutt, exhibits protective effects against diabetic nephropathy and possesses antioxidative, antidiabetic, antihypertensive, and anti-hyperlipidemic properties [1] [2].'

Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek.

LXR antagonist 2 (compound 10rr) is a potent LXR (liver X receptor) inverse agonist, acting on LXRβ (IC50: 0.36 μM) and LXRα (IC50: 2.25 μM). LXR antagonist 2 is an adipogenesis inhibitor that downregulates LXR target genes SREBP-1c, ACC, FAS and SCD-1. LXR antagonist 2 exhibits hypolipidemic activity in Triton WR-1339-induced hyperlipidemic mice.

S-2E is a compound that functions as an orally active, noncompetitive inhibitor of both HMG-CoA reductase and acetyl-CoA carboxylase. It exhibits an anti-hyperlipidemic action, making it suitable for studying conditions such as familial hypercholesterolemia and mixed hyperlipidemia [1] [2].

β-Boswellic acid (Beta-boswellic acid) and its derivatives (the major constituents of Boswellin) have anti-carcinogenic, anti-tumor, and anti-hyperlipidemic activities.

beta-Amyrin acetate inhibits HMG-CoA Reductase (HMGCR) and sEH activity with IC50 of 3.4 μM. beta-Amyrin acetate has anti-inflammatory, antifungal, antioxidant, and anti-hyperlipidemic activities.

Flavanomarein demonstrates potent antioxidative property, including free radical scavenging activity, inhibition of lipid peroxidation, as well as lipid-lowering effects in human HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs).

YM-750 is a potent inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), with an IC50 value of 0.18 μM. ACAT is an enzyme that catalyzes the conversion of cholesterol and long-chain fatty-acyl-coenzyme A into cholesteryl esters.

Acitemate(Chinoin 123) has an inhibitory effect on atherosclerosis and reduces the permeability of the aorta in rabbits fed a hyperlipidemic diet, which can be used to study atherosclerosis.

N,N'-Diacetyl-L-cystine (DiNAC) is the disulphide dimer of N-acetylcysteine with immunomodulating properties. N,N'-diacetyl-L-cystine also has antiatherosclerotic effects in Watanabe-heritable hyperlipidemic rabbit (WHHL) rabbits. N,N'-diacetyl-L-cystine is also an effective and orally active modulator of contact sensitivity/delayed-type hypersensitivity reactions in rodents.

ONO-4817 is a broad-spectrum matrix metalloproteinase (MMP) inhibitor that potentially mitigates atherosclerotic neointimal proliferation and atheromatous plaque progression by suppressing matrix metalloproteinases (MMPs). It effectively reduces the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbits [1].

Probucol (DH-581), an anti-hyperlipidemic drug, can lower the level of cholesterol in the bloodstream by increasing the LDL catabolic rate.

Cholestenone is an intermediate oxidation product of cholesterol that is metabolized primarily in the liver. It can cause long-term defects in cell function. It is highly mobile in membranes and affects cholesterol turnover and efflux.